|
|
|
|
POZEN Submits New Drug Application For VIMOVO' (PN 400)
POZEN Inc.(NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC) naproxen and...
|
|
|
POZEN Submits New Drug Application For VIMOVO (PN 400)
POZEN Inc.(NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC) naproxen and...
|
|
|
POZEN Submits New Drug Application For VIMOVO (PN 400)
POZEN Inc.(NASDAQ:POZN),today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC) naproxen and...
|
|
|
Knee Osteoarthritis After Anterior Cruciate Ligament Injury: A Systematic Review
Winner of the 2008 Systematic Review Competition A Systematic Review Britt Elin iestad, PT, MSc*,, Lars Engebretsen, MD, PhD, Kjersti Storheim, PT, PhD and May Arna Risberg, PT, PhD From the Norwegian Research Center for Active...
|
|
|
Computed Tomography Topographic Mapping of Subchondral Density (CT-TOMASD) in Osteoarthritic and Normal Knees:
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Osteoarthritis and Cartilage , 06/30/09 Print Save in My Library Free Abstract Johnston JD et al.- CT-TOMASD offers precise 3D measures of...
|
|
|
POZEN Submits New Drug Application For VIMOVO (PN 400)
The NDA submission is based on data from a comprehensive clinical trials program.POZEN conducted two pivotal studies (301/302) under a special protocol assessment agreed with the FDA, which met their primary endpoints. In the 301/302...
|
|
|
POZEN Submits New Drug Application For VIMOVO„ (PN 400)
POZEN Inc.(NASDAQ:POZN) The NDA submission is based on data from a comprehensive clinical trials program. POZEN conducted two pivotal studies (301/302) under a special protocol assessment agreed with the FDA, which met their primary...
|
|
|
POZEN Submits New Drug Application For VIMOVO (PN 400)
- POZEN Inc.(NASDAQ:POZN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC) naproxen and...
|
|
|
Sleep as a Marker in the Effective Management of Chronic Osteoarthritis Pain with Opioid Analgesics
Seminars in Arthritis and Rheumatism, 06/29/09 Turk DC et al.- In each of the 10 placebo-controlled studies identified, concurrent improvements in pain intensity and measured sleep disturbances were observed in patients receiving the long...
|
|
|
Shots over Surgery
Suffering from a torn ligament or tendon doesn't always have to mean going under the knife.Now one local doctor is offering a non-invasive treatment that's giving patients pain-relief. Seven's Diana Diaz shows us why some are choosing....
|
|
|
TopAbstracts in Osteoarthritis 06/25/2009
TopAbstracts in Osteoarthritis are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer...
|
|
|
Hand Osteoarthritis: An Epidemiological Perspective
Seminars in Arthritis and Rheumatism, 06/26/09 Print Save in My Library Free Abstract Kalichman L et al.- Hand OA is a heterogeneous, age- and gender-dependent disorder, occurring more frequently in women over 50 years of age. In the...
|
|
|
Arthritis basics - Prevention & Treatment
Arthritis afflicts half of Americans age 65 and older, according to the U.S.National Institutes of Health. Arthritis causes deterioration within the joints that serve as cushion between bones. The cartilage covering the end of the...
|
|
|
Meniscal Tears in Osteoarthritis: Ignore or Operate?
_ Meniscal Tears in Osteoarthritis: Ignore or Operate?.
|
|
|
Early Detection of Osteoarthritis May Provide Possibility for a Cure
Researchers are investigating potential biomarkers in dogs for early diagnosis of osteoarthritis, which could help identify patients at increased risk of developing the degenerative joint disease.Osteoarthritis is typically...
|
|
|
Is Obesity a Risk Factor for Progressive Radiographic Knee Osteoarthritis?
_ Is Obesity a Risk Factor for Progressive Radiographic Knee Osteoarthritis?.
|
|
|
Clinical Trials Update: June 22, 2009
(HealthDay News) -- Here are the latest clinical trials, courtesy of ClinicalConnection.com and CenterWatch: Osteoarthritis of the Hip This study is being conducted across the United States for people with osteoarthritis of the hip.
National Womens Health Information Center:
Jun 22 2009 6:42PM
Matching: osteoarthritis knee
|
Find similar documents
|
|
|
|
Use of patient-reported THR, TKR outcomes helps surgeons identify who will do poorly
According to results of a patient-based questionnaire used by research assistant Vikki Wylde and her colleagues, poor outcomes occurred in 13% of patients after total hip replacement (THR), 17% after total knee replacement (TKR) and 45...
|
|
|
TR BioSurgical, LLC Develops Breakthrough Osteoarthritis Implant
TR BioSurgical, LLC, announced highly encouraging results using their new medical device (bioscaffold) in canine patients with advanced osteoarthritis.The new bioscaffold is implanted in or near diseased tissue and provides a structural...
|
|
|
The Effect of Low-Level Laser in Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Trial
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Photomedicine and Laser Surgery, 06/17/09 Print Save in My Library Free Abstract Hegedus B et al.- The authors' results show that LLLT reduces pain in KOA...
|
|
|
NicOx: additional 24?hour blood pressure results for naproxcinod presented at the European Meeting on Hyperten
-- NicOx S.A.(NYSE Euronext Paris: COX) today announced that additional results from the 111 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod were presented on Saturday, June 13, at the European Meeting on Hypertension ...
|
|
|
Chondroitin Sulphate Effective in Patients With Concomitant Knee Osteoarthritis and Psoriasis: Presented at EU
my personal edition> osteoarthritis > news E-Mail this DGDispatch to a colleague DGDispatch COPENHAGEN, Denmark -- June 15, 2007 -- Treatment of knee osteoarthritis with chondroitin sulphate (Condrosan) in patients with...
|
|
|
A Second Cycle of Injectable Hyaluronic Acid for Knee Osteoarthritis Pain Is Safe, Effective: Presented at EUL
my personal edition> osteoarthritis > news E-Mail this DGDispatch to a colleague DGDispatch COPENHAGEN -- June 14, 2009 -- A second cycle of hyaluronic acid (hylan) G-F 20 injection therapy is safe for treating patients with...
|
|
|
CombinatoRx Provides Positive Result For Knee Osteoarthritis Trial
Synavive is a dissociated glucocorticoid and prednisolone for pain relief in knee osteoarthritis Related News Vaccine produced at Novartis plant in Marburg, Germany ...Regeneron to receive royalties on worldwide sales of canakinumab...
|
|
|
NicOx SA (NCOX.F): Additional 24 Hour Blood Pressure Results for Raproxcinod Presented at the European Meeting
- Highlighted Links www.nicox.com NicOx S.A.(NYSE Euronext Paris: COX) today announced that additional results from the 111 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod were presented on Saturday, June 13, at the...
|
